180 Life Sciences

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on developing novel drugs to address unmet needs in inflammatory diseases, fibrosis, and pain, leveraging the combined expertise of distinguished therapy specialists from Oxford University. 180 Life Sciences is leading this research to tackle one of the world’s largest disease drivers—inflammation. The company is advancing groundbreaking research into clinical programs, seeking to develop new drugs for isolated inflammatory conditions that currently lack effective therapies. The company's primary platform involves a novel approach utilizing anti-TNF (tumor necrosis factor) treatments for fibrosis.